07:00 , May 25, 2009 |  BioCentury  |  Regulation

PDX coverage gap

The future of the U.S. diagnostics industry, and hopes that personalized medicine can be transformed from a slogan into reality, hinge in large measure on payers learning to discern which genetic tests provide clinically valuable...
07:00 , Jul 7, 2008 |  BioCentury  |  Strategy

Flurizan’s failure adds value

Myriad Genetics Inc. and partner H. Lundbeck A/S were surely disappointed when Flurizan tarenflurbil failed a Phase III trial to treat mild Alzheimer’s disease. But investors made it very clear that they would rather the...
07:00 , May 20, 2002 |  BC Week In Review  |  Company News

Myriad Genetics sales and marketing update

MYGN launched Colaris AP predictive medicine product to determine a patient's risk of hereditary colon cancer. The product detects mutations in the APC gene , which cause familial adenomatous polyposis (FAP) and attenuated FAP, both...